Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

BUFFALO, N.Y., March  02, 2020  (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, provided an update today that its partner, Almirall, announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for tirbanibulin ointment for the treatment of actinic keratosis.

Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Athenex (ATNX) Q4 Earnings Expected to Decline

BUFFALO, N.Y., Feb.  03, 2020  (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex, Inc. (Nasdaq: ATNX), informed shareholders he received a notice of a proposed administrative fine of RMB 100,000 (approximately $14,300) from the China Securities Regulatory Commission (“CSRC”), for a matter unrelated to Athenex. 

Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

A Small Bet On Athenex

Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Athenex

Athenex: Compelling Overall Survival Advantage For Oral Paclitaxel, Revaluation In Progress

Lannett Company

Elite is on track to become profitable for the first time

Not All Strategic Transformations Are Elite, But This One Is

Humana

Insider buying can be an encouraging signal for potential investors. A beneficial owner added to a stake in a biopharma company last week.

Notable Insider Buys In The Past Week: Athenex And Humana

Boston Scientific

ConforMIS

Dare Bioscience

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

The agreement covers China, Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies.

Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

Investors did not see the clinical trial results they wanted.

Here's Why Athenex Stock Is Sliding Today

Shares of Athenex Inc.  fell 19% in morning trading.

Athenex shares fall 19% in morning trading

Allergan

Alector Inc

Amarin Corporation Plc

Biohaven Pharmaceutical Hld

Cara Therapeutics

Global Blood Therapeutics

Intra-Cellular Therapies

Novartis

Puma Biotechnology

Protagonist Therapeutics

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

Seagen

Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.

2 Breast Cancer Fighting Stocks to Invest In

BUFFALO, N.Y., Dec.  05, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into an agreement for the sale of its common stock in a private placement with a group of institutional investors. The lead investor in the private placement is Kingdon Capital Management, LLC. The transaction is expected to result in gross proceeds to Athenex of approximately $60 million, before deducting offering expenses. Net proceeds from the transaction are expected to be used to fund clinical development and regulatory activities for oral paclitaxel and encequidar; regulatory activities for tirbanibulin ointment for the treatment of actinic keratosis; commercialization activities, including pre-launch activities for oral paclitaxel and encequidar; manufacturing infrastructure; and working capital and general corporate purposes.

Athenex Announces $60 Million Private Placement

The title of a scientific abstract suggests that additional data from its lead pipeline program will bolster the case for regulatory approval.

Here's Why Athenex Gained Over 43% Today

Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2019 Results - Earnings Call Transcript

Dynavax Technologies

Farfetch

Nabriva Therapeutics

SNDL Inc.

Investors want to know which stocks are set to take flight. We are talking about stocks with serious growth prospects here, or names that can more than double investors’ returns in the next year.

7 “Strong Buy” Stocks With Triple-Digit Growth Prospects

Earnings Preview: Athenex (ATNX) Q3 Earnings Expected to Decline

BUFFALO, N.Y., Oct.  30, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan Designations from the European Commission (EC) for paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of soft tissue sarcoma, following a positive opinion from the European Medicines Agency (EMA).

Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

BUFFALO, N.Y., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a progress update from partner Almirall on tirbanibulin ointment (also known as ALM14789, formerly known as KX-01 or KX2-391) for the treatment of actinic keratosis (AK).

Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

Shares jump after news breaks that a big investor recently added to its position.

Why Athenex's Stock Is Flying High Today

BUFFALO, N.Y., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has completed construction of its new API (active pharmaceutical ingredients) facility in Chongqing, China. The 440,000-square-foot facility will produce validation batches in the fourth quarter of 2019 and is expected to commence operations in the first half of 2020. The construction of the facility is part of Athenex’s strategy for vertical integration in order to capture value across the supply chain. Once operational, the facility is expected to expand the company’s API production capabilities to further support its global clinical development needs and ensure the supply of API for commercial launches.

Athenex Completes Construction of New API Facility in Chongqing

BUFFALO, N.Y., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will be making an oral presentation at the San Antonio Breast Cancer Symposium (SABCS) 2019, to be held December 10 – 14, 2019, in San Antonio, Texas, on its Phase III study of oral paclitaxel and encequidar (“Oral Paclitaxel”; f.k.a. Oraxol or oral paclitaxel and HM30181A) in metastatic breast cancer.

Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

BUFFALO, N.Y., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present several posters highlighting clinical data from three of its ongoing programs for oral paclitaxel and encequidar (“Oral Paclitaxel”; f.k.a Oraxol or oral paclitaxel and HM30181) at the European Society for Medical Oncology (ESMO) Congress 2019 to be held September 27 – October 1, 2019 in Barcelona, Spain. The posters demonstrate the results from clinical studies of Oral Paclitaxel for patients with a number of advanced solid tumor types as well as in combination with ramucirumab, an anti-VEGFR2 antibody therapy.

News for Athenex Stock (ATNX)